Bedrijfsoverzicht
Serina Therapeutics, Inc. is a biotechnology entity focused on the development of pharmaceutical compounds designed to address neurological disorders and pain management. The company operates within the Healthcare sector, specifically the Biotechnology industry, which typically involves high-risk research and development activities with long timelines to commercialization. Its total market capitalization stands at $24.38M, while its trailing twelve-month revenue is recorded at $130,000. The company lists N/A employees in its official filings, which indicates that precise staffing levels are either undisclosed or not tracked in standard public datasets for this specific reporting period. These financial metrics collectively suggest that the company is an early-stage or micro-cap entity with minimal current revenue generation relative to its market valuation. The extremely low revenue figure compared to its market cap highlights a significant gap between investor expectations and current operational output, characteristic of firms in preclinical development stages. This disparity implies that the market is pricing the company based on potential future asset value rather than existing cash flow or sales performance.
Financiële gezondheid
Serina Therapeutics reported a net income of $-19,436,000 and an EBITDA of $-23,949,000 against a revenue base of only $130,000 for the trailing twelve-month period. The substantial negative gap between the negligible revenue and the deep net income loss reveals a cost structure heavily weighted toward research and development expenses rather than cost of goods sold. The company generated a free cash flow of $-11,285,875, indicating a continuous cash burn that limits its financial flexibility for sustaining operations without external capital raises. Analysis of the three primary margins shows a gross margin of 0.0%, an operating margin of -18478.5%, and a profit margin of 0.0%, all reflecting the high burn rate typical of biotechnology firms before product approval. The company holds $3.06M in cash but carries $3.32M in debt, resulting in a debt-to-equity ratio listed as N/A due to the absence of positive shareholders' equity. The current ratio is calculated at 1.71, suggesting the company possesses sufficient current assets to cover its short-term liabilities, though this liquidity buffer is constrained by the overall negative equity position. Return on Equity stands at -8159.2% and Return on Assets at -219.6%, metrics that mathematically indicate the company is currently destroying shareholder value and utilizing assets inefficiently in a traditional profitability sense.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not applicable (N/A) due to negative earnings, while the forward P/E is listed as -1.89, a figure that does not reflect traditional valuation multiples for a loss-making company. The difference between these metrics, or the lack thereof, implies that standard earnings-based valuation models cannot be applied to forecast future earnings trajectories without significant restructuring or successful product milestones. The price-to-book ratio is -4.29, indicating that the market values the company's equity at a negative multiple relative to its book value, which often occurs when intangible assets like intellectual property are not fully captured on the balance sheet. The price-to-sales ratio is 187.55 and the EV/EBITDA is -1.24, suggesting that the market is pricing the stock based on speculative future potential rather than current sales performance or earnings generation. The 52-week high is $7.92 and the 52-week low is $1.22, placing the current trading environment within a wide historical range that reflects high volatility typical of small-cap biotech stocks. The beta value is 0.10, indicating that the stock price is significantly less volatile than the broader market, moving in a highly defensive manner despite its high risk profile inherent to the biotechnology sector.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between the top line and the bottom line. The absence of positive revenue growth data implies that the company is not yet in a commercial scaling phase where earnings could theoretically outpace or lag sales figures. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all available cash to fund its research and development pipeline rather than distributing income to shareholders. The sustainability of a dividend is not a concern since no dividends are paid, and the company reinvests its limited cash reserves and potential future funding into advancing its lead product candidate, SER 252. The overall growth and income profile is characterized by zero current profitability and no income distribution, relying entirely on future successful clinical outcomes to alter the current financial trajectory.